Biotest Aktiengesellschaft (ETR:BIO3)

Germany · Delayed Price · Currency is EUR · Preferred Stock

32.00

-0.20 (-0.62%)

Apr 15, 2026, 8:16 AM CET

20.75% (1Y)

Market Cap	1.35B
Revenue (ttm)	635.20M -18.8%
Net Income	-24.50M
EPS	-0.63
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	0.04 (0.13%)
Ex-Dividend Date	Jul 3, 2025

Volume	60
Average Volume	2,562
Open	32.00
Previous Close	32.00
Day's Range	32.00 - 32.00
52-Week Range	24.60 - 32.00
Beta	n/a
RSI	13.60
Earnings Date	Mar 27, 2026

About ETR:BIO3

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomega... [Read more]

Industry Biological Products, Except Diagnostic Substances

Sector Healthcare

Founded 1946

Employees 2,495

Stock Exchange Deutsche Börse Xetra

Ticker Symbol BIO3